Abstract:JNK3, a member of the MAPK family, plays a pivotal role in mediating cellular responses to stress signals, with its activation implicated in a myriad of inflammatory conditions. While JNK3 holds promise as a therapeutic target for neurodegenerative disorders such as Huntington's, Parkinson's, and Alzheimer's diseases, there remains a gap in the market for effective JNK3 inhibitors. Despite some pan-JNK inhibitors reaching clinical trials, no JNK-targeted therapies have achieved market approval. To bridge this gap, our study introduces a sophisticated virtual screening approach. We begin with an energy-based screening, subsequently integrating a variety of rescoring techniques. These encompass glide docking scores, MM/GBSA, and artificial scoring mechanisms such as Deep-Dock and advanced Graph Neural Networks. This virtual screening workflow is designed to evaluate and identify potential small-molecule inhibitors with high binding affinity. We have implemented a virtual screening workflow to identify potential candidate molecules. This process has resulted in the selection of ten molecules. Subsequently, these ten molecules have undergone biological activity evaluation to assess their potential efficacy. Impressively, molecule compound 6 surfaced as the most promising, exhibiting a potent kinase inhibitory activity marked by an IC50 of 130.1 nM and a notable reduction in TNF-alpha release within macrophages. This suggests that compound 6 could potentially serve as an effective inhibitor for the treatment of neuroinflammation and neurodegenerative diseases. The prospect of further medicinal modifications to optimize compound 6 presents a promising avenue for future research and development in this field. Utilizing binding pose metadynamics coupled with molecular dynamics simulations, we delved into the explicit binding mode of compound 6 to JNK3. Such insights pave the way for refined drug development strategies. Collectively, our results underscore the efficacy of the hybrid virtual screening workflow in the identification of robust JNK3 inhibitors, holding promise for innovative treatments against neuroinflammation and neurodegenerative disorders.

Insights into the c-Jun N-terminal kinase 3 (JNK3) inhibitors: CoMFA, CoMSIA analyses and molecular docking studies

Identifying New Ligands for JNK3 by Fluorescence Thermal Shift Assays and Native Mass Spectrometry

Identification of Potential JNK3 Inhibitors: A Combined Approach Using Molecular Docking and Deep Learning-Based Virtual Screening

Live-cell Imaging and Profiling of C-Jun N-terminal Kinases Using Covalent Inhibitor-Derived Probes.

Identify of promising isoquinolone JNK1 inhibitors by combined application of 3D-QSAR, molecular docking and molecular dynamics simulation approaches

Structural Requirements of Isoquinolones As Novel Selective C-Jun N-terminal Kinase 1 Inhibitors: 2D and 3D QSAR Analyses.

Rational Modification, Synthesis and Biological Evaluation of 3,4-Dihydroquinoxalin-2(1h)-one Derivatives As Potent and Selective C-Jun N-terminal Kinase 3 (JNK3) Inhibitors.

Selective Covalent Inhibiting JNK3 by Small Molecules for Parkinson's Diseases

Unraveling the Design and Discovery of C-Jun N-Terminal Kinase Inhibitors and Their Therapeutic Potential in Human Diseases.

Identification of potential JNK3 inhibitors through virtual screening, molecular docking and molecular dynamics simulation as therapeutics for Alzheimer's disease

Design, synthesis and biological evaluation of novel O-substituted tryptanthrin oxime derivatives as c-Jun N-terminal kinase inhibitors

Identification of Chinese Herbal Compounds with Potential As JAK3 Inhibitors.

Computational Study of the Selectivity Mechanism of Aminopyrazole Inhibitors for c-Jun N-terminal kinase 3 over p 38

Development of a Covalent Inhibitor of C-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.

Structural Basis and Biological Consequences for JNK2/3 Isoform Selective Aminopyrazoles

Multistage Screening Reveals 3-Substituted Indolin-2-one Derivatives As Novel and Isoform-Selective C-Jun N-terminal Kinase 3 (JNK3) Inhibitors: Implications to Drug Discovery for Potential Treatment of Neurodegenerative Diseases.

JNK3 inhibitors as promising pharmaceuticals with neuroprotective properties

Theoretical Exploring Selective-Binding Mechanisms of JAK3 by 3D-QSAR, Molecular Dynamics Simulation and Free Energy Calculation

Ligand-based 3D pharmacophore design, virtual screening and molecular docking for novel p38 MAPK inhibitors

Discovery of Novel c-Jun N-Terminal Kinase 1 Inhibitors from Natural Products: Integrating Artificial Intelligence with Structure-Based Virtual Screening and Biological Evaluation

Discovery of Novel Indazole Chemotypes As Isoform-Selective JNK3 Inhibitors for the Treatment of Parkinson's Disease